<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00753142</url>
  </required_header>
  <id_info>
    <org_study_id>898-2003</org_study_id>
    <nct_id>NCT00753142</nct_id>
  </id_info>
  <brief_title>Mechanism Underlying Beta-cell Failure in Obese African Americans With History of Hyperglycemic Crises</brief_title>
  <official_title>Mechanism Underlying Beta-cell Failure in Obese African Americans With History of Hyperglycemic Crises</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>American Diabetes Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Emory University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Obesity is common in African-American patients with newly diagnosed diabetes who present with
      diabetic ketoacidosis (DKA).1 Despite the presentation with severe symptoms of insulinopenia
      and ketoacidosis, clinical and immunogenetic observations indicate that most obese AA
      patients with DKA have type 2 diabetes. In such patients, our previous studies reveal: a) at
      presentation, obese AA patients with DKA have markedly de-creased pancreatic insulin
      secretion, lower than in obese non-DKA patients admitted with comparable hyperglycemia, but
      significantly greater than in lean patients with DKA;2 b) aggressive diabetic management
      results in significant improvement in b-cell function and insulin sensitivity sufficient to
      allow discontinuation of insulin therapy within 3 months of follow-up.2, 3 Based on these
      observations we conclude that similar to obese patients with hyperglycemia, most obese AA
      with DKA have type 2 diabetes, and that although defects in both insulin secretion and
      insulin action are present, transient b-cell failure is the primary defect in the development
      of ketoacidosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Obese AA patients with a history of DKA who later experience near-normoglycemia remission
      represent an ideal population in which to define the sequence of events that lead to b-cell
      dysfunction in type 2 diabetes. We hypothesize that obese AA with DKA will prove particularly
      susceptible to b-cells dysfunction due to sustained elevations of plasma glucose (glucose
      toxicity) and/or free fatty acid levels (lipotoxicity).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2004</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>First Phase Insulin Release (FPIR)</measure>
    <time_frame>at the end of 20 hours</time_frame>
    <description>Calculated as the sum of the insulin levels at 2, 3, 4, and 5 min after infusion</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To Determine if Hyperglycemia-induced Reduced Insulin Secretion is the Result of Beta-cell Exhaustion or Beta-cell Desensitization.</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Hyperglycemia</condition>
  <arm_group>
    <arm_group_label>Subjects with ketosis-prone diabetes</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Obese African-Americans with type 2 diabetes with history of diabetic ketoacidosis (DKA)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subjects with ketosis-resistant diabetes</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Obese African-American with type 2 diabetes with hyperglycemia but without ketosis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Obese African-American nondiabetic subjects</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intralipid 20%</intervention_name>
    <description>48hr infusion with intralipid at 40ml/hr</description>
    <arm_group_label>Subjects with ketosis-prone diabetes</arm_group_label>
    <arm_group_label>Subjects with ketosis-resistant diabetes</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glucose infusion</intervention_name>
    <description>Glucose infusion for 20 hours at 200 mg/m2/min</description>
    <arm_group_label>Subjects with ketosis-prone diabetes</arm_group_label>
    <arm_group_label>Subjects with ketosis-resistant diabetes</arm_group_label>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Obese African American subjects (BMI equal or greater than 30)

          2. age 18-65,

          3. patients with a history of diabetic ketoacidosis as defined by the ADA criteria

          4. patients admitted with hyperglycemia but without ketoacidosis (BG greater than
             400ml/dl without evidence of ketosis/ketones

          5. obese nondiabetic controls (BMI &gt;30; ruled out for diabetes with a 75g oral glucose
             tolerance test)

        Exclusion Criteria:

          1. patients with positive autoimmune markers [islet cell (ICA) or Glutamic acid
             decarboxylase (GAD) autoantibodies];

          2. patients with significant medical or surgical illness, including but not limited to
             myocardial ischemia, congestive heart failure, chronic renal insufficiency, liver
             failure, and infectious processes;

          3. patients with recognized or suspected endocrine disorders associated with increased
             insulin resistance, such as hypercortisolism, acromegaly, or hyperthyroidism;

          4. patients with bleeding disorders, thrombocytopenia, or abnormalities in coagulation
             studies;

          5. patients with fasting hyperglycemia (blood glucose &gt; 120 mg/dl) after discontinuation
             of insulin therapy, and 6) pregnancy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guillermo Umpierrez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Grady Memorial Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Gosmanov AR, Smiley D, Robalino G, Siqueira JM, Peng L, Kitabchi AE, Umpierrez GE. Effects of intravenous glucose load on insulin secretion in patients with ketosis-prone diabetes during near-normoglycemia remission. Diabetes Care. 2010 Apr;33(4):854-60. doi: 10.2337/dc09-1687. Epub 2010 Jan 12.</citation>
    <PMID>20067967</PMID>
  </results_reference>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2008</study_first_submitted>
  <study_first_submitted_qc>September 15, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2008</study_first_posted>
  <results_first_submitted>July 7, 2014</results_first_submitted>
  <results_first_submitted_qc>July 7, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 1, 2014</results_first_posted>
  <last_update_submitted>July 7, 2014</last_update_submitted>
  <last_update_submitted_qc>July 7, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 1, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Emory University</investigator_affiliation>
    <investigator_full_name>Guillermo Umpierrez</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Hyperglycemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperglycemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Soybean oil, phospholipid emulsion</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients with DKA and/or severe hyperglycemia will be admitted to Grady Memorial Hospital in Atlanta, GA and will be followed in the diabetes clinic at Grady Hospital General Clinical Research Center and/or Diabetes Clinic</recruitment_details>
      <pre_assignment_details>Control arm: 2 hour glucose level had be less than 140 mg/dL after a 75g oral glucose tolerance test</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Subjects With Ketosis-prone Diabetes</title>
          <description>Diabetic subjects that presented with high blood glucose levels and ketosis at time of diagnosis</description>
        </group>
        <group group_id="P2">
          <title>Subjects With Ketosis-resistant Diabetes</title>
          <description>Diabetic subjects that presented with high blood glucose levels without ketosis at time of diagnosis</description>
        </group>
        <group group_id="P3">
          <title>Nondiabetic Control Subjects</title>
          <description>overweight/obese subjects without diabetes</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Subjects With Ketosis-prone Diabetes</title>
          <description>Diabetic subjects that presented with high blood glucose levels and ketosis at time of diagnosis</description>
        </group>
        <group group_id="B2">
          <title>Subjects With Ketosis-resistant Diabetes</title>
          <description>Diabetic subjects that presented with high blood glucose levels without ketosis at time of diagnosis</description>
        </group>
        <group group_id="B3">
          <title>Nondiabetic Control Subjects</title>
          <description>overweight/obese subjects without diabetes</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="7"/>
            <count group_id="B3" value="13"/>
            <count group_id="B4" value="28"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42.8" spread="10.6"/>
                    <measurement group_id="B2" value="49.7" spread="8.1"/>
                    <measurement group_id="B3" value="40" spread="9.3"/>
                    <measurement group_id="B4" value="44" spread="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>First Phase Insulin Release (FPIR)</title>
        <description>Calculated as the sum of the insulin levels at 2, 3, 4, and 5 min after infusion</description>
        <time_frame>at the end of 20 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Subjects With Ketosis-prone Diabetes</title>
            <description>Diabetic subjects that presented with high blood glucose levels and ketosis at time of diagnosis</description>
          </group>
          <group group_id="O2">
            <title>Subjects With Ketosis-resistant Diabetes</title>
            <description>Diabetic subjects that presented with high blood glucose levels without ketosis at time of diagnosis</description>
          </group>
          <group group_id="O3">
            <title>Nondiabetic Control Subjects</title>
            <description>Overweight/obese subjects without diabetes</description>
          </group>
        </group_list>
        <measure>
          <title>First Phase Insulin Release (FPIR)</title>
          <description>Calculated as the sum of the insulin levels at 2, 3, 4, and 5 min after infusion</description>
          <units>microunits/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="359" spread="42"/>
                    <measurement group_id="O2" value="381" spread="147"/>
                    <measurement group_id="O3" value="299" spread="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Determine if Hyperglycemia-induced Reduced Insulin Secretion is the Result of Beta-cell Exhaustion or Beta-cell Desensitization.</title>
        <time_frame>4 years</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Subjects With Ketosis-prone Diabetes</title>
          <description>Diabetic subjects that presented with high blood glucose levels and ketosis at time of diagnosis</description>
        </group>
        <group group_id="E2">
          <title>Subjects With Ketosis-resistant Diabetes</title>
          <description>Diabetic subjects that presented with high blood glucose levels without ketosis at time of diagnosis</description>
        </group>
        <group group_id="E3">
          <title>Nondiabetic Control Subjects</title>
          <description>Overweight/obese subjects without diabetes</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>hyperglycemia</sub_title>
                <description>blood sugar intermittently &gt; 300</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Guillermo Umpierrez</name_or_title>
      <organization>Emory University</organization>
      <phone>404-778-1665</phone>
      <email>geumpie@emory.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

